TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37194051

Group type: EXPERIMENTAL
Intervention: Electronic screening for tobacco use during COVID
Number of subjects: 3904

Group type: EXPERIMENTAL
Intervention: Electronic screening for any substance use during COVID
Number of subjects: 3904

Group type: EXPERIMENTAL
Intervention: Electronic screening for suicidal ideation during COVID
Number of subjects: 3904

Group type: COMPARATOR
Intervention: Electronic screening for depression
Number of subjects: 3904

Group type: COMPARATOR
Intervention: Electronic screening for anxiety
Number of subjects: 3904

Group type: COMPARATOR
Intervention: Electronic screening for alcohol use
Number of subjects: 3904

Group type: COMPARATOR
Intervention: Electronic screening for cannabis use
Number of subjects: 3904
Study: 37194068

Group type: EXPERIMENTAL
Intervention: Individualized dosing of follitropin delta (average daily dose 11.0 ± 1.6 µg, duration 10.3 ± 1.6 days)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Individualized dosing of follitropin delta
Number of subjects: 104
Study: 37194074

Group type: EXPERIMENTAL
Intervention: Group well child care provided on-site at a maternal substance use disorder treatment program.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Individual well child care from a nearby pediatric primary care clinic.
Number of subjects: 108
Study: 37194089

Group type: EXPERIMENTAL
Intervention: Virtual hospital rounds using telehealth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37194094

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 37194104

Group type: EXPERIMENTAL
Intervention: Patients with AN
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 43
Study: 37194253

Group type: EXPERIMENTAL
Intervention: Ketamine infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched GA TRD sample
Number of subjects: 0
Study: 37194288

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 97
Study: 37194394

Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg once daily
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg once daily
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg and 60 mg once daily
Number of subjects: 218
Study: 37194432

Group type: EXPERIMENTAL
Intervention: Polysomnographic (PSG)-based sleep disturbances
Number of subjects: 131
Study: 37194458

Group type: EXPERIMENTAL
Intervention: Preoperative hyper-polypharmacy (greater than or equal to 10 medications)
Number of subjects: 55997

Group type: EXPERIMENTAL
Intervention: Preoperative polypharmacy (5-9 medications)
Number of subjects: 55997

Group type: COMPARATOR
Intervention: Non-polypharmacy (fewer than 5 medications)
Number of subjects: 55997

Group type: EXPERIMENTAL
Intervention: Preoperative hyper-polypharmacy
Number of subjects: 55997

Group type: EXPERIMENTAL
Intervention: Preoperative polypharmacy
Number of subjects: 55997

Group type: COMPARATOR
Intervention: Non-polypharmacy
Number of subjects: 55997

Group type: COMPARATOR
Intervention: Patients not exposed to polypharmacy
Number of subjects: 55997

Group type: EXPERIMENTAL
Intervention: Patients exposed to preoperative polypharmacy
Number of subjects: 55997
Study: 37194488

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 1.5 mg/kg intravenous infusion, administered 15 minutes prior to surgery
Number of subjects: 12
Study: 37194618

Group type: EXPERIMENTAL
Intervention: Compression Garments (CG) combined with Physiotherapy (PT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 36
Study: 37194813

Group type: EXPERIMENTAL
Intervention: Medium intensity coughing technique during subcutaneous low molecular weight heparin injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 100
Study: 37194964

Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP)
Number of subjects: 92
Study: 37195023

Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: paxalisib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ONC201 and paxalisib
Number of subjects: 0
Study: 37195063

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 2761

Group type: COMPARATOR
Intervention: Placebo (PBO) + Methotrexate (MTX)
Number of subjects: 2761
Study: 37195128

Group type: EXPERIMENTAL
Intervention: ICI combined with chemotherapy
Number of subjects: 211

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 211
Study: 37195144

Group type: EXPERIMENTAL
Intervention: NightWatch intervention for nocturnal seizure detection
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: NightWatch intervention
Number of subjects: 53
Study: 37195370

Group type: EXPERIMENTAL
Intervention: Non-invasive assessment of myocardial PD-L1 expression
Number of subjects: 0
Study: 37195407

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (LEBQ2W)
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Any dose of lebrikizumab (All-LEB)
Number of subjects: 1720
Study: 37195423

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs)
Number of subjects: 18
Study: 37195518

Group type: EXPERIMENTAL
Intervention: Progressive resistance tongue exercise using pressure sensors for 12 weeks with usual care
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 19
Study: 37195666

Group type: EXPERIMENTAL
Intervention: Deliberate practice intervention (3 weekly, 30-minute video-conferenced sessions with personalized feedback)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care (passive control)
Number of subjects: 72
Study: 37195667

Group type: EXPERIMENTAL
Intervention: SIB-RT with concurrent and consolidated oral S-1 chemotherapy (CRTCT group)
Number of subjects: 330

Group type: COMPARATOR
Intervention: SIB-RT alone (RT group)
Number of subjects: 330
Study: 37195676

Group type: EXPERIMENTAL
Intervention: Emergency Department process improvement package with a focus on collaborative safety planning
Number of subjects: 2761
Study: 37195787

Group type: EXPERIMENTAL
Intervention: Selective extended dissection (SED)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard dissection (SD)
Number of subjects: 520
Study: 37195906

Group type: EXPERIMENTAL
Intervention: Jumpstart intervention (stigma focused counseling)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Jumpstart intervention (for participants 30 and older)
Number of subjects: 177
Study: 37195924

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) strategy using Health Scouts
Number of subjects: 1903
Study: 37195941

Group type: EXPERIMENTAL
Intervention: 700 mg of peresolimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37195942

Group type: EXPERIMENTAL
Intervention: Emodepside
Number of subjects: 266
Study: 37195999

Group type: EXPERIMENTAL
Intervention: PfRAS vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noninfectious mosquito bites (mock vaccination)
Number of subjects: 0
Study: 37196017

Group type: EXPERIMENTAL
Intervention: Kato-Katz
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Mini-FLOTAC
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Kato-Katz with NS survey design
Number of subjects: 5000

Group type: COMPARATOR
Intervention: WHO recommended SS survey design
Number of subjects: 5000
Study: 37196061

Group type: EXPERIMENTAL
Intervention: PXVX0317 vaccine
Number of subjects: 0
Study: 37196069

Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiotherapy (hFSRT) combined with 1500 mg Durvalumab on day 5, followed by infusions every 4 weeks for up to 12 months.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hypofractionated stereotactic radiotherapy (hFSRT)
Number of subjects: 6
Study: 37196158

Group type: EXPERIMENTAL
Intervention: 9MW2821
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enfortumab vedotin (EV)
Number of subjects: 0
Study: 37196396

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for OSAS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desensitization with a reward system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Improved communication with medical team and equipment company
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Use of visual supports and social support for education
Number of subjects: 40
Study: 37196404

Group type: EXPERIMENTAL
Intervention: Advance care planning information provision by general practitioners (GPs)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Advance care planning discussions involving GPs and/or relatives
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Facilitators of ACP discussions
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Barriers to ACP discussions
Number of subjects: 25
Study: 37196421

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37196527

Group type: EXPERIMENTAL
Intervention: Metarrestin (ML-246) administered orally at a dose of 1 mg
Number of subjects: 0
Study: 37196637

Group type: EXPERIMENTAL
Intervention: Social deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37196799

Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (8 kPa)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Higher oxygenation target (12 kPa)
Number of subjects: 335
Study: 37197707

Group type: EXPERIMENTAL
Intervention: Invasive approach (intra-arrest transport with in-hospital ECPR initiation)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Standard ACLS
Number of subjects: 286
Study: 37197785

Group type: EXPERIMENTAL
Intervention: Type III OI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Type IV OI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Type VI OI
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: General OI population
Number of subjects: 37
Study: 37197808

Group type: EXPERIMENTAL
Intervention: Lower levels of medical and allied healthcare professional (AHP) staff
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lower levels of support staff
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lower levels of AHP support
Number of subjects: 138
Study: 37197841

Group type: EXPERIMENTAL
Intervention: Takotsubo syndrome (TTS)
Number of subjects: 24
Study: 37197845

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 462
Study: 37197904

Group type: EXPERIMENTAL
Intervention: Motorised spiral enteroscopy (MSE)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 125
Study: 37197905

Group type: EXPERIMENTAL
Intervention: Test, treat, retest and re-treat initial treatment failures
Number of subjects: 15057

Group type: EXPERIMENTAL
Intervention: Family members of a positive index case
Number of subjects: 15057
Study: 37197909

Group type: EXPERIMENTAL
Intervention: NSTE-ACS with left circumflex (LCx) occlusion
Number of subjects: 4412

Group type: COMPARATOR
Intervention: NSTE-ACS with right coronary artery (RCA) occlusion
Number of subjects: 4412

Group type: COMPARATOR
Intervention: NSTE-ACS with left anterior descending coronary artery (LAD) occlusion
Number of subjects: 4412

Group type: EXPERIMENTAL
Intervention: NSTE-ACS with total coronary occlusion (TCO)
Number of subjects: 4412
Study: 37198021

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 booster dose
Number of subjects: 150
Study: 37198160

Group type: EXPERIMENTAL
Intervention: Automated clinical decision support system (alert group)
Number of subjects: 5060

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5060
Study: 37198293

Group type: EXPERIMENTAL
Intervention: Longuette™ chimney stent-graft for left subclavian artery revascularization
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Longuette™ chimney stent-graft
Number of subjects: 34
Study: 37198558

Group type: EXPERIMENTAL
Intervention: VR-based stereoptic serious games
Number of subjects: 30

Group type: COMPARATOR
Intervention: Refractive correction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (age-matched healthy individuals)
Number of subjects: 30
Study: 37198562

Group type: EXPERIMENTAL
Intervention: Moderate to high intensity physical activity program (45 min, 3 times per week, lasting 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 37198670

Group type: EXPERIMENTAL
Intervention: 12-week e-health intervention following a 2-week brisk-walking training
Number of subjects: 184

Group type: COMPARATOR
Intervention: 12-week conventional behavioural change intervention following a 2-week brisk-walking training
Number of subjects: 184
Study: 37198686

Group type: EXPERIMENTAL
Intervention: Brensocatib
Number of subjects: 0
Study: 37198687

Group type: EXPERIMENTAL
Intervention: Serious game 'Broodles' played over a period of 4 weeks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 154
Study: 37199326

Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with quad-shot radiotherapy (14.8 Gy in four twice-daily fractions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Quad-shot radiotherapy
Number of subjects: 15
Study: 37199401

Group type: EXPERIMENTAL
Intervention: Red meat intake (≥4 servings/wk)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Legume intake (≥4 servings/wk)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Animal-sourced iron intake (highest quartile)
Number of subjects: 2293

Group type: EXPERIMENTAL
Intervention: Total dietary iron and overall plant-sourced iron intake
Number of subjects: 2293
Study: 37199424

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 82
Study: 37199427

Group type: EXPERIMENTAL
Intervention: Maternal tenofovir disoproxil fumarate-based antiretroviral treatment (mART)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Infant nevirapine prophylaxis (iNVP)
Number of subjects: 400
Study: 37199438

Group type: EXPERIMENTAL
Intervention: Hip Fracture Injection (HiFI) - multimodal local injection of bupivacaine, morphine sulfate, ketorolac at the fracture site during surgery
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no HiFI)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Hip Fracture Injection (HiFI)
Number of subjects: 184
Study: 37199436

Group type: EXPERIMENTAL
Intervention: Stress ball during endoscopy (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 60
Study: 37199608

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37199745

Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR) 600 mg/m
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of fenretinide plus safingol
Number of subjects: 16
Study: 37199775

Group type: EXPERIMENTAL
Intervention: Target walking task
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal walking task
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Various walking speeds (0.3 m/s, 0.5 m/s, 0.9 m/s, and preferred)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Reliability assessment
Number of subjects: 15
Study: 37199789

Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocytes ≤ 5% at baseline
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: GPI-deficient granulocytes > 30% at baseline
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: Abdominal pain
Number of subjects: 2813
Study: 37199884

Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 6 mg BID, titrated to 12 mg BID if necessary, later replaced by 15/30 mg once-daily extended-release equivalents
Number of subjects: 493
Study: 37199921

Group type: EXPERIMENTAL
Intervention: Parental reminiscing training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 37199932

Group type: EXPERIMENTAL
Intervention: Early childhood Family Check-Up (FCU) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37199977

Group type: EXPERIMENTAL
Intervention: SENSE Theatre (Experimental group)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Active Control Condition (Tackling Teenage Training, TTT)
Number of subjects: 290
Study: 37200022

Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine-tipiracil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Trifluridine-tipiracil alone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Panitumumab plus trifluridine-tipiracil (subgroup with ctDNA analysis)
Number of subjects: 62
Study: 37200037

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery (PCS)
Number of subjects: 870
Study: 37200067

Group type: EXPERIMENTAL
Intervention: Facebook advertisement campaign
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Recruitment cost
Number of subjects: 70
Study: 37200547

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Social Work and Self-Care (MBSWSC) programme
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active control (modified mindfulness-based programme)
Number of subjects: 62
Study: 37200720

Group type: EXPERIMENTAL
Intervention: Inclined position (head elevations of 0°, 10°, 18°, and 28°)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study: 37200903

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 57
Study: 37200944

Group type: EXPERIMENTAL
Intervention: High energy-dense oral nutritional supplement (edONS, 2.4 kcal/mL)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Reference oral nutritional supplement (heONS, 2.0 kcal/mL)
Number of subjects: 103
Study: 37200972

Group type: EXPERIMENTAL
Intervention: Kinocardiography (KCG) technology
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal LVEF ≥50%)
Number of subjects: 30
Study: 37200995

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 634
Study: 37201078

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel combined with LBP and tegafur
Number of subjects: 10
Study: 37201155

Group type: EXPERIMENTAL
Intervention: Multi-task deep learning (DL) radiomic model incorporating liquid biopsy (LB) parameters including circulating tumor cell (CTC) features.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid biopsy (LB) technique using circulating tumor cell (CTC) parameters.
Number of subjects: 0
Study: 37201438

Group type: EXPERIMENTAL
Intervention: Remotely delivered, individualized, and self-directed gait modification with weekly telerehabilitation appointments and remote monitoring
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed control group (wait period before intervention)
Number of subjects: 20
Study: 37201510

Group type: EXPERIMENTAL
Intervention: Interleukin-8-secreting CD4 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-cell profile
Number of subjects: 0
Study: 37201546

Group type: EXPERIMENTAL
Intervention: Immediate Sequential Bilateral Cataract Surgery (ISBCS)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Delayed Sequential Bilateral Cataract Surgery (DSBCS)
Number of subjects: 865
Study: 37201747

Group type: EXPERIMENTAL
Intervention: M-TAPA (40 ml 0.25% bupivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: M-TAPA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (surgical infiltration)
Number of subjects: 60
Study: 37201751

Group type: EXPERIMENTAL
Intervention: CANKADO-active arm
Number of subjects: 499

Group type: COMPARATOR
Intervention: CANKADO-inform arm
Number of subjects: 499
Study: 37201757

Group type: EXPERIMENTAL
Intervention: Stereotactic Accelerated Partial Breast Irradiation (APBI) at 30 Gy in 5 fractions
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Stereotactic Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 204
Study: 37201756

Group type: EXPERIMENTAL
Intervention: Preoperative Proton Beam Therapy with Concurrent Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37201900

Group type: EXPERIMENTAL
Intervention: Ketamine intravenous therapy (KIT) induction
Number of subjects: 2758

Group type: EXPERIMENTAL
Intervention: Ketamine intravenous therapy (KIT) maintenance
Number of subjects: 2758

Group type: COMPARATOR
Intervention: Ketamine intravenous therapy (KIT) at eight weeks
Number of subjects: 2758
Study: 37202039

Group type: EXPERIMENTAL
Intervention: Nutritional therapy received in the first days of intensive care admission
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Functional capacity assessment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mortality assessment
Number of subjects: 103
Study: 37202042

Group type: COMPARATOR
Intervention: ω-3 fatty acid ethyl esters (4 g/day)
Number of subjects: 20
Study: 37202059

Group type: EXPERIMENTAL
Intervention: KETO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EXO
Number of subjects: 8

Group type: COMPARATOR
Intervention: ISO
Number of subjects: 8

Group type: COMPARATOR
Intervention: FAST
Number of subjects: 8
Study: 37202073

Group type: EXPERIMENTAL
Intervention: Semi-elemental enteral formula with partially hydrolyzed guar gum (PHGG) at 12 g/L
Number of subjects: 24